RB1 and neoplasm: Confirming that biallelic RB1 mutations are somatic, resulting in the consequential reduction in risk of bilateral tumours, has the benefit of reducing the frequency of future screening required for the patient and the reassurance of low risk to their relatives, while confirming the exact germline mutation present can aid detection of mutation carriers in other family members.